Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04852120
Other study ID # 000373
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 1, 2021
Est. completion date December 31, 2022

Study information

Verified date July 2023
Source Ferring Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

High-quality bowel preparation plays an important role in ensuring a safe and successful X-ray examination, endoscopy or some kinds of bowel surgeries. Inadequate bowel preparation may lead to incomplete examination of the colonic mucosa, may require increased operation time and difficulty, and incur the costs for rescheduling or performing other examinations. Early attention to the influencing factors of bowel cleansing effect and taking positive measures can effectively improve the success rate and diagnosis rate of endoscopic and radiological examinations, and reduce the possibility of postoperative complications and local infections. In 2019, China released the latest "Guidelines for Bowel Preparation Related to Digestive Endoscopy", emphasizing the importance of dietary restrictions and patient notification and education. The "Guideline" also recommends that sodium picosulfate, magnesium oxide, and anhydrous citric acid can be used for bowel preparation before endoscopy and is well tolerated (recommended strength: weak; evidence quality: moderate). The other used colonic cleansing agents also include polyethylene glycol (PEG) electrolyte powder, magnesium salt, sodium phosphate, mannitol and Chinese herbal medicine. Each carries its own properties, indications and safety profiles. Compound Sodium Picosulfate Granules is a compounded preparation consisting of sodium picosulfate and magnesium citrate. Each sachet contains 10 mg of sodium picosulfate, 3.5 g of magnesium oxide and 12.0 g of citric acid. It is white to slightly yellow crystalline powder, with a slight orange flavour. Sodium picosulfate is transformed by colonic bacteria to form an active metabolite: bis-(p-hydroxyphenyl)-pyridyl-2-methane, Bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which acts directly on the colonic mucosa to stimulate colonic peristalsis. Magnesium oxide and citric acid react to create magnesium citrate (when dispersed in a solution), which is an osmotic agent that causes water to be retained within the gastrointestinal tract. The stimulant laxative activity of sodium picosulfate together with the osmotic laxative activity of magnesium citrate produces a purgative effect, which can be used to clean the bowel prior to X-ray examination, endoscopy or bowel surgery. Since its first marketing in the United Kingdom (UK) in December 1980, Compound Sodium Picosulfate Granules has been approved in more than 80 countries and regions, including Germany (2010), France (2010), Spain (2011), Italy (2011), United States (2012) and Japan (2016), under the tradename PICOLAX, PICOPREP or PREPOPIK. In 2018, Compound Sodium Picosulfate Granules was officially approved in China with the indication: for preparation of bowel cleansing prior to X-ray examination, endoscopy or surgery when judged clinically necessary.


Recruitment information / eligibility

Status Completed
Enrollment 3000
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients who have been prescribed Ferring Compound Sodium Picosulfate Granules - Agree to participate in this study and sign the informed consent form (ICF). Exclusion Criteria: - Patients who are enrolled in other on-going studies, which prohibit any participation in this non-interventional study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No intervention
Compound Sodium Picosulfate Granules administered by the patient prior to X-ray examination, endoscopy or surgery when judged clinically necessary in accordance to usual practice consistent with the local prescribing information.

Locations

Country Name City State
China Ferring Investigational Site Beijing
China Ferring Investigational Site Dalian
China Ferring Investigational Site Fuzhou
China Ferring Investigational Site Jingdezhen
China Ferring Investigational Site Nanjing
China Ferring Investigational Site Ningbo
China Ferring Investigational Site Qiqihar
China Ferring Investigational Site Xian

Sponsors (2)

Lead Sponsor Collaborator
Ferring Pharmaceuticals DeltaMed

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Known Adverse Drug Reactions (ADRs) An adverse drug reaction (ADR) is characterized by the suspicion of a causal relationship between the medicine and the occurrence, i.e. judged as being at least possibly related to treatment by the reporter or a reviewing health professional.
An ADR is a response to a medicinal product which is noxious and unintended. This includes adverse reactions which arise from:
The use of a medical product within the terms of the marketing authorization;
The use outside the terms of the marketing authorization, including overdose, off-label use, misuse, abuse and medication errors;
Occupational exposure.
Up to 37(+2) hours after drug administration
Primary Occurrence of Unexpected Adverse Events (AEs)/ADRs Adverse event (AE) is any untoward medical condition or the deterioration of a pre-existing medical condition in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
Unexpected adverse reaction refers to a drug reaction whose nature, severity, specificity, or outcome is not consistent with the term or description listed in the current local/regional label. This includes events that may be symptomatically and pathophysiological related to an event listed in the labelling but differ from the event because of greater severity or specificity.
Up to 37(+2) hours after drug administration
Primary Incidence and Risk Factors of Serious Adverse Events (SAEs)/Serious Adverse Drug Reactions (SADRs) The incidence below is Syncope.
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose that:
Results in death
Is life-threatening
Is a congenital anomaly/birth defect
Results in persistent or significant disability/incapacity
Results in unplanned inpatient hospitalisation or prolongation of existing hospitalisation
Is an important medical event that may jeopardise the participant or may require intervention to prevent one of the outcomes listed above
Up to 37(+2) hours after drug administration
See also
  Status Clinical Trial Phase
Completed NCT02630680 - Eziclen Drug Utilisation in Real Life Setting
Completed NCT05032794 - Unrestricted Diet for Screening Colonoscopy N/A
Completed NCT02239692 - A Trial Comparing the PICOPREP Tailored Dosing Schedule to the PICOPREP Day-before Dosing Schedule for Colon Cleansing in Preparation for Colonoscopy Phase 3
Unknown status NCT01481714 - Efficacy and Safety of Split-dose Citrafleet Administered From 2 to 6 Hours Before Morning Colonoscopies Phase 4
Completed NCT02321462 - Efficacy, Safety and Tolerability of Eziclen in Adult Subjects Undergoing Colonoscopy Phase 3
Recruiting NCT04054388 - LINE Re-education Before Colonoscopy to Confirm Optimal Bowel Cleansing N/A
Completed NCT01864915 - Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule Phase 3
Completed NCT03631446 - Drug Use-Results Survey on Picoprep® Combination Powder
Recruiting NCT05354609 - DWI MR-enterography Without or With Bowel Cleansing to Assess Intestinal Inflammatory Activity in the Follow-up of Crohn's Disease N/A